Adults aged 18-65 with a definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months (not exceeding 10 years), may qualify to participate. Total disease duration greater than 10 years is permitted. Individuals must have at least 50% scalp hair loss.
Participants will receive investigational oral medication (active study drug) or placebo. Investigational medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may also be provided.
Study participation will last about 32 weeks and involve about 10 visits to the study centre.